Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sentra AM is a **medical food** formulated as a proprietary blend of amino acids (including choline bitartrate, L-glutamic acid, acetyl L-carnitine), cocoa extract (providing theobromine), Ginkgo biloba, hawthorn berry, and dextrose, designed for the dietary management of metabolic processes associated with **fatigue and cognitive disorders**. Its mechanism centers on restoring and maintaining acetylcholine balance to support neurotransmitter synthesis and activity—specifically to improve symptoms of fatigue and cognitive impairment thought to result from altered neurotransmitter metabolism. Its ingredients are considered GRAS (Generally Recognized As Safe) and are present in physiologically routine dietary amounts, but in specific ratios to elicit a clinical effect. Sentra AM does not demonstrate significant pharmacokinetic interaction with conventional pharmaceuticals and must be taken under physician supervision[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sentra AM.